Phase I trial of docetaxel administered by weekly infusion in patients with advanced refractory cancer.

@article{Hainsworth1998PhaseIT,
  title={Phase I trial of docetaxel administered by weekly infusion in patients with advanced refractory cancer.},
  author={John D Hainsworth and Howard A. Burris and Joan B Erland and Melodie Thomas and Frank Anthony Greco},
  journal={Journal of clinical oncology : official journal of the American Society of Clinical Oncology},
  year={1998},
  volume={16 6},
  pages={2164-8}
}
PURPOSE Docetaxel is a highly active antineoplastic agent; however, grade IV leukopenia occurs in the large majority of patients treated with a dose of 100 mg/m2 every 3 weeks. Recent experience with weekly paclitaxel has demonstrated a bone marrow-sparing effect when a weekly administration schedule is used. We investigated a weekly schedule of docetaxel… CONTINUE READING